Fetching financial data...

Bruker Corporation

Data period: Annual Quarterly Graham uses annual
NASDAQ · Healthcare
Bruker Corporation
BRKR · Medical Devices
$61.58
▲ 0.24 (0.39%)
Cached · 10 min
Overall Grade
D
Defensive
D
Enterprising
Profitability
D
Gross Profit Margin 49.6%
Operating Margin 9.9%
Net Income Margin -6.2%
Fin. Health
D
Years to Pay Off Debt -35.1 yrs
Working Capital vs Long-Term Debt -$794M
Working Capital $1.0B
Valuation
F
Price-to-Book 3.94x
Cash Flow
C
Free Cash Flow -$106M
Owner Earnings $35M
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
Metric Explanations
What each dimension measures and where the thresholds come from.
Gross Profit Margin
Revenue minus cost of goods sold. Graham's ≥40% threshold identifies businesses with durable pricing power. Note: software and financial companies naturally exceed this; retailers and manufacturers rarely reach it due to their cost structures.
Operating Margin
Profit after operating costs before interest and taxes. A consistent ≥15% operating margin signals a business with real competitive advantages. Capital-intensive industries (airlines, auto, commodities) rarely hit this threshold due to their structural cost base — compare within industry for context.
Net Income Margin
Bottom-line profit as a percentage of revenue. The ≥20% target reflects Buffett's preference for highly profitable businesses. Financial engineering (buybacks, tax optimisation) can inflate this temporarily — look for consistency across multiple years rather than a single strong result.
Years to Pay Off Debt
Total Debt ÷ Net Income. Lower = stronger balance sheet. Important caveat: utilities, telecoms, REITs, and infrastructure companies carry large structural debt by design — their bond-like cash flows service it comfortably at ratios that would alarm Graham. Compare within sector.
Working Capital vs Long-Term Debt
Working Capital minus Long-Term Debt. Negative results are common and expected in capital-return-focused businesses like Apple, Domino's, and McDonald's — where aggressive buybacks and dividends intentionally reduce book equity. This does not indicate financial distress in high-FCF businesses.
Working Capital
Current Assets minus Current Liabilities. Negative working capital can be a deliberate efficiency strategy in businesses that collect cash before paying suppliers (retailers, fast food franchises, subscription businesses). Assess alongside free cash flow generation for full context.
Price-to-Book
Market price vs book value per share. Rarely below 1.5x for quality businesses today. Intangible assets (brand, software, patents) don't appear on the balance sheet under accounting rules, making P/B artificially high for asset-light companies like software and consumer brands.
Free Cash Flow
Operating cash flow minus capital expenditures. Buffett's most important metric — cash a business actually generates for its owners after maintaining and growing its asset base. Consistently positive FCF is one of the strongest indicators of a durable, well-run business regardless of accounting profits.
Owner Earnings
Net Income + Depreciation & Amortisation − Capital Expenditures. Buffett's preferred measure of a company's true annual earning power — what could theoretically be distributed to owners without impairing the business. More reliable than reported EPS because it accounts for the capital cost of maintaining the business.
Market Cap $9.4B
Enterprise Value $11.1B
P/E (TTM) 25.76
Dividend Yield 0.33%
Exchange NASDAQ
Gross Profit 49.6%
Operating Margin 9.9%
Net Margin -6.2%
Sector Healthcare
Industry Medical Devices
Employees 11085
Country United States
Showing Key Metrics
Income Highlights
Metric Q2 2026 Q4 2025 Q4 2024
Gross Profit % 49.6% 46.0% N/A
Operating Margin % 9.9% 11.4% N/A
Net Income % -6.2% 2.7% N/A
Diluted EPS -0.41 0.10 N/A
Balance Sheet Highlights
Metric Q2 2026 Q4 2025 Q4 2024
Total Assets $6.1B $6.2B N/A
Total Debt $1.8B $2.0B N/A
Working Capital $1.0B $933M N/A
Years to Pay Debt -35.09 78.57 N/A
Cash Flow Highlights
Metric Q2 2026 Q4 2025 Q4 2024
Free Cash Flow -$106M $178M N/A
Owner Earnings $35M $136M N/A
CapEx % of Net Income N/A 200.0% N/A
📊 Quarterly mode — Graham Fair Value & 7 Criteria require annual data. Switch to Annual for full analysis.
Quarter vs Same Quarter Last Year
YoY strips seasonality
Revenue Growth (YoY)
Prior year: $797M ▲ $838M +5.2%
Revenue growth vs same quarter last year strips seasonality. Consistent double-digit growth is a Buffett hallmark.
Gross Margin
Prior year: 44.9% ▲ 49.6% +4.7pp
Buffett: consistent gross margin above 40% signals durable pricing power and competitive moat.
Operating Margin
Prior year: 10.4% ▲ 9.9% -0.5pp
Graham: operating margin reflects true business economics before financing. Trend matters as much as level.
Net Margin
Prior year: 1.0% ▼ -6.2% -7.2pp
Net margin can be distorted by one-time items, tax timing, or interest costs — compare to operating margin for signal quality.
Quarterly Health Checks
3 Graham/Buffett criteria that are valid and reliable on quarterly data
✅ Adequate Size
Graham required scale for resilience. Quarterly revenue × 4 gives an annualised proxy.
$838M/qtr (≈$3.4B ann.)
vs > $1.5B annualised revenue
❌ Financial Condition
Current assets vs current liabilities — a real-time liquidity snapshot. Valid and reliable on quarterly data.
1.85x current ratio
vs ≥ 2.0x
❌ Free Cash Flow
Buffett's most important single metric. A positive FCF quarter means the business generated real cash for owners after maintaining its asset base.
-$106M
vs Positive
Operating Cash Flow
-$77M
Latest quarter · Buffett's cash reality check
ROIC
1.3%
Based on latest annual operating income
Return on Invested Capital — Buffett's preferred measure for asset-light businesses. ROIC > 15% consistently signals a durable competitive advantage (moat). More meaningful than P/B for software, pharma, and consumer brand companies where most value is intangible and off-balance-sheet.
Market Cap / Net Assets
3.9x
Net Assets: $2.4B
⚠️ Net margin compressed 7.2pp vs same quarter last year. Common causes: one-time charges (restructuring, write-downs, legal settlements), tax rate changes, or rising interest expense. Check the income statement notes before drawing conclusions about operating health.
⚠️ Operating income is positive but net income is negative. This typically reflects below-the-line items: interest expense, impairment charges, tax adjustments, or one-time write-offs. The core business may be healthy — operating margin is a better signal of ongoing profitability here.
Peers & Industry Comparison
Medical Devices — Auto-detected peers
Company Price Market Cap P/E Gross Margin Net Margin Revenue
BRKR $61.58 $9.4B 25.76 49.6% -6.2% $838M
MDT
Medtronic plc.
$91.75 $117.4B 22.6 65.3% 13.9% $37.5B
ABT
Abbott Laboratories
$102.98 $178.2B 33.3 56.8% 11.6% $46.6B
SYK
Stryker Corporation
$274.19 $105.2B 28.4 65.6% 14.4% $25.8B
BSX
Boston Scientific Corporation
$43.72 $63.4B 17.7 69.2% 17.5% $21.0B
EW
Edwards Lifesciences Corporatio
$88.34 $50.9B 52.6 77.8% 15.4% $6.5B
"The management of a business is its most important single factor — more important than market position, patents, or financial structure."
— Benjamin Graham
Capital Allocation & Alignment
Insider Ownership
26.97%
High — management has strong skin in the game
Return on Equity (ROE)
-2.2%
Weak — poor returns on equity
Return on Assets (ROA)
-0.9%
Poor — assets are not generating adequate returns
Share Buybacks (Latest Year)
$10M
Management is returning capital to shareholders via buybacks
Debt Trend YoY
+9.2% YoY
Debt is roughly stable
Leadership Team
Frank Laukien Ph.
Chairman, CEO & President
Age 65
Pay: $1,594,872
Gerald Herman CPA
Executive VP & CFO
Age 67
Pay: $879,311
Mark Munch Ph.
Corporate Executive VP and President of Bruker Nano Group & Corporate
Age 63
Pay: $1,119,503
Juergen Srega
President of Bruker Biosystems Group & Bruker Daltonics Division
Age 70
Pay: $772,590
Wolfgang Pusch Ph.
President of Bruker Microbiology & Infection Diagnostics Group
Top Institutional Holders
Institution % Owned Shares
FMR, LLC 13.28% 20,237,425
Orbis Allan Gray Ltd 11.77% 17,940,076
Blackrock Inc. 7.49% 11,407,332
Pallas Capital Advisors Llc 6.22% 9,483,978
Vanguard Portfolio Management LLC 3.21% 4,888,290
Vanguard Capital Management LLC 3.19% 4,859,252
Sculptor Capital LP 3.04% 4,625,000
State Street Corporation 2.64% 4,017,673
Risk Analysis
Beta (Market Risk)
1.26
Moderate volatility — moves slightly more than market
Short Interest
15.2% of float
Heavy short selling — market has significant bearish bets
Debt-to-Equity
0.76x
Conservative balance sheet — low financial risk
Current Ratio
1.85x
Adequate liquidity
52-Week Price Range
Low: $30.09 Current: $61.58 High: $65.30
Currently at 89% of 52-week range

Bruker Corporation (BRKR) fundamental analysis — Overall grade D based on profitability, financial health, valuation and cash flow. Graham's Fair Value: N/A (negative EPS). Gross profit margin: 49.6%. Operating margin: 9.9%. Net margin: -6.2%. Market cap: $9.4B. Sector: Healthcare. Industry: Medical Devices. Analysis powered by 360investing — free fundamental stock analysis based on Benjamin Graham and Warren Buffett principles.

Disclaimer: 360investing is provided for informational and educational purposes only and does not constitute financial, investment, legal, or tax advice. All data is sourced from public third-party providers and may be delayed, inaccurate, or incomplete. Past performance is not indicative of future results. Analysis, scores, and valuations are algorithmic and do not represent professional investment recommendations. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decision. Use of this tool constitutes acceptance that 360investing and its operators bear no liability for decisions made based on information presented here.

Data Sources & Methodology Privacy Policy